Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives $56.33 Consensus Price Target from Brokerages

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has been assigned a consensus rating of “Moderate Buy” from the eight analysts that are covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $56.3333.

AGIO has been the subject of several analyst reports. Scotiabank cut their price target on shares of Agios Pharmaceuticals from $71.00 to $65.00 and set a “sector outperform” rating for the company in a report on Monday, July 28th. Bank of America cut their price target on shares of Agios Pharmaceuticals from $52.00 to $51.00 and set a “buy” rating for the company in a report on Tuesday, July 22nd. Finally, Wall Street Zen downgraded shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, May 19th.

Insider Activity

In related news, CEO Brian Goff sold 18,700 shares of Agios Pharmaceuticals stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $33.54, for a total transaction of $627,198.00. Following the completion of the transaction, the chief executive officer directly owned 105,401 shares of the company’s stock, valued at $3,535,149.54. This trade represents a 15.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider James William Burns sold 2,799 shares of Agios Pharmaceuticals stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $33.54, for a total transaction of $93,878.46. Following the transaction, the insider directly owned 28,650 shares of the company’s stock, valued at $960,921. This represents a 8.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 57,448 shares of company stock worth $2,026,141 over the last ninety days. Corporate insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On Agios Pharmaceuticals

A number of institutional investors have recently modified their holdings of the stock. Bellevue Group AG raised its stake in shares of Agios Pharmaceuticals by 2.1% in the second quarter. Bellevue Group AG now owns 3,590,150 shares of the biopharmaceutical company’s stock worth $119,408,000 after acquiring an additional 75,000 shares during the last quarter. Commodore Capital LP raised its stake in shares of Agios Pharmaceuticals by 6.4% in the second quarter. Commodore Capital LP now owns 2,325,000 shares of the biopharmaceutical company’s stock worth $77,330,000 after acquiring an additional 140,000 shares during the last quarter. Erste Asset Management GmbH raised its stake in shares of Agios Pharmaceuticals by 10.9% in the first quarter. Erste Asset Management GmbH now owns 2,229,900 shares of the biopharmaceutical company’s stock worth $65,439,000 after acquiring an additional 220,000 shares during the last quarter. Jefferies Financial Group Inc. bought a new position in shares of Agios Pharmaceuticals in the fourth quarter worth about $49,290,000. Finally, Geode Capital Management LLC raised its stake in shares of Agios Pharmaceuticals by 0.8% in the second quarter. Geode Capital Management LLC now owns 1,405,755 shares of the biopharmaceutical company’s stock worth $46,762,000 after acquiring an additional 11,174 shares during the last quarter.

Agios Pharmaceuticals Stock Performance

NASDAQ:AGIO opened at $38.80 on Monday. The company has a 50-day moving average of $36.82 and a 200-day moving average of $32.89. The company has a market capitalization of $2.25 billion, a price-to-earnings ratio of 3.53 and a beta of 0.80. Agios Pharmaceuticals has a 52 week low of $23.42 and a 52 week high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported ($1.93) EPS for the quarter, missing analysts’ consensus estimates of ($1.74) by ($0.19). The business had revenue of $12.50 million for the quarter, compared to the consensus estimate of $9.46 million. Agios Pharmaceuticals had a negative return on equity of 3.49% and a net margin of 1,590.42%. Sell-side analysts forecast that Agios Pharmaceuticals will post -6.85 EPS for the current year.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.